Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Return on Sales (2024 - 2026)

Prelude Therapeutics' Return on Sales history spans 3 years, with the latest figure at 0.03% for Q1 2026.

  • On a quarterly basis, Return on Sales changed N/A to 0.03% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.05%, a N/A change, with the full-year FY2025 number at 0.09%, up 11.0% from a year prior.
  • Return on Sales hit 0.03% in Q1 2026 for Prelude Therapeutics, down from 0.03% in the prior quarter.
  • Over the last five years, Return on Sales for PRLD hit a ceiling of 0.03% in Q4 2025 and a floor of 0.11% in Q3 2024.
  • Historically, Return on Sales has averaged 0.06% across 3 years, with a median of 0.03% in 2025.
  • The widest YoY moves for Return on Sales: up 8bps in 2025, down 5bps in 2025.
  • Tracing PRLD's Return on Sales over 3 years: stood at 0.08% in 2024, then surged by 64bps to 0.03% in 2025, then fell by -1bps to 0.03% in 2026.
  • Business Quant data shows Return on Sales for PRLD at 0.03% in Q1 2026, 0.03% in Q4 2025, and 0.03% in Q3 2025.